Losing half of its value, Genta Inc.'s stock slid south on Tuesday following news that Genasense did not meet key secondary endpoints and had safety issues in a Phase III trial, causing Aventis to drop out as a marketing partner. (BioWorld Today)

Just a few days after the re-election of President Bush, the U.S. government awarded VaxGen Inc. an $877.5 million contract to supply anthrax vaccine for civilian defense. (BioWorld Today)